T1- and T2-mediated allogeneic GVT effects. (A) Allogeneic BMT model. CB6F1 mice were lethally irradiated and given B6 BM cells on day 0. All mice received 0.1 × 106 TSA breast cancer cells except for the BM control group (n = 7). Some mice received only the donor B6 BM cells (TSA control; n = 28), whereas other mice received BM supplemented with 10 × 106 in vitro generated donor B6 T1 (n = 15) or T2 (n = 15) cells. (B) Syngeneic BMT model. CD3/CD28-generated T1 and T2 populations were generated from CB6F1 mice and administered to lethally irradiated syngeneic CB6F1 hosts inoculated with TSA breast cancer cells (n = 5 per T1 and T2 BMT groups). (C) Allogeneic BMT model using fasL-deficient gld T1 cells. T1 cells from B6 wild-type (n = 12) or B6 gld (n = 14) mice were generated using CD3/CD28 stimulation and administered to lethally irradiated allogeneic CB6F1 hosts inoculated with TSA breast cancer cells. (D) Percentage body weight change (from day 0).
